



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

DIGITAL LIFE LINE PTE. LTD. SIGNED LICENSING AGREEMENT WITH NATIONAL UNIVERSITY HOSPITAL AND NATIONAL UNIVERSITY OF SINGAPORE TO COMMERCIALISE CATARACT DIAGNOSTIC DEVICE

SINGAPORE – 8 January, 2025 — DISA Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”), is pleased to announce that Digital Life Line Pte. Ltd. (“**DLL**”), a subsidiary of DiSa Digital Safety Pte. Ltd. which is a wholly-owned subsidiary of the Company, has signed a tri-party licensing agreement with the National University Hospital (Singapore) (“**NUH**”) and National University of Singapore (“**NUS**”) on 7 January 2025 to commercialise the Mobile Imaging Device for Anterior Segment (“**MIDAS**”), a portable device registered with Health Science Authority of Singapore, designed for cataract screening in primary care settings to bring high-quality ophthalmic care into the community.

With a rapidly ageing population, chronic eye conditions such as cataracts are becoming increasingly prevalent. Despite the availability of safe, cost-effective treatments, age-related cataracts remain the leading cause of visual impairment worldwide. It is estimated that around 95 million people globally are affected by cataracts, with vision impairment occurring in 35.1 million people¹. According to the International Agency for the Prevention of Blindness, cataract is a leading cause of complete vision loss, accounting for one-third of global blindness².

In Singapore, over 80 per cent of people aged 60 and above have some form of cataract, according to a study carried out by the Singapore National Eye Centre³. Although cataract is almost always treatable, a significant number of patients with cataract remains undiagnosed due to limited availability of or accessibility to cataract screening. In Singapore, more than two-thirds of those suffering from visually significant cataract were unaware of their condition, which may result in delays in treatment and hinder improvements in their visual functioning⁴.

MIDAS is a portable smartphone slit lamp imaging device that was designed for use by patients, nurses, primary care physicians such as general practitioners, polyclinic doctors and emergency physicians for cataract screening. The device is used with smartphones to image the eyes’ lens to ascertain the level of cloudiness that correlates with the severity of cataracts. This provides information to identify individuals who need to be referred to cataract specialists for follow-up, enabling effective triaging of cataract surgery candidates within the community to ensure early intervention while reducing non-urgent referrals.

Developed by the Department of Ophthalmology at the NUH and Centre for Innovation, Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore (“**NUS Medicine**”), DLL is pleased to continue with the research and development of MIDAS and to commercialise MIDAS to address the increasing need to bring tertiary-level ophthalmology directly into the community. By combining proprietary hardware and software features, MIDAS can empower patients, nurses, primary care physicians with an easy-to-use, artificial intelligence-enabled cataract screening without the involvement of ophthalmologists.



Perspective view of MIDAS device attached on a smartphone

How the MIDAS device can be used to image the patient's eye

“We are honoured to be given another opportunity to work with NUH and NUS to commercialise MIDAS in Singapore and hopefully, regionally in the near future. With our portable artificial intelligence-powered cataract screening device, we are bringing advanced eye care directly to the community. Our in-house developed AI-algorithms can eliminate the need for trained staff to identify the best image and process the cataract grading parameters within 10 seconds. By harnessing intelligent triaging based on an established cataract grading system, we aim to ensure that each referral is both timely and accurate.” said Mr. Eddie Chng, the Managing Director and Chief Executive Officer of DLL and the Company.

¹ Liu, Yu-Chi, et al. "Cataracts." *The Lancet* 390.10094 (2017): 600-612.

² Khairallah, Moncef, et al. "Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010." *Investigative ophthalmology & visual science* 56.11 (2015): 6762-6769.

³ <https://www.healthxchange.sg/head-neck/eye-care/cataracts-causes-symptoms-treatment>

⁴ Chua, Jacqueline, et al. "Prevalence, risk factors, and impact of undiagnosed visually significant cataract: the Singapore epidemiology of eye diseases study." *PLoS One* 12.1 (2017): e0170804.

About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technology innovations to enhance outcomes, reduce costs, improve efficiencies within the healthcare and consumer industry.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of product and services that optimises efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.

Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542

Telephone number: +65 6232 3210